热门资讯> 正文
Codexis股价在CEO交接中下滑
2022-07-19 04:52
- Codexis, Inc. (NASDAQ:CDXS) has appointed Dr. Stephen Dilly, Board member, and biotechnology veteran, as President and CEO, effective August 9, 2022.
- After ten years of leading the transformation and growth of Codexis, the current President and CEO, John Nicols, will step down for personal reasons.
- Mr. Nicols will remain on Codexis' Board through the annual meeting in June 2023 and will assume a new multi-year role as Strategic Advisor to provide ongoing support to the company.
- Most recently, Dr. Stephen Dilly served as President and CEO of Sierra Oncology through its recent sale to GlaxoSmithKline (NYSE:GSK) for $1.9 billion.
- Previously, he served as CEO of Aimmune Therapeutics, acquired by Nestle Health Science for $2.6 billion. He holds an MBBS and a Ph.D. in Cardiac Physiology from the University of London.
- Recently,
- Last week, Codexis released the preliminary revenue expectations for Q2, which were lower than the prior guidance.
- Price Action: CDXS shares are trading lower by 2.79% at $6.62 during the post-market session on Monday.
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
